We report on 14 patients treated with linac- or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrence from prostate cancer, up to the mean dose of 30 Gy/3 fractions. At the mean follow-up of 18.6 months, five patients experienced clinical out-field progression. Toxicity was minimal. Further investigation is warranted in order to identify the patients that benefit most from this treatment modality and to define the optimal association of such local approach with androgen deprivation. Hopefully, effective local therapy might reduce the burden of systemic therapies given to the recurrent/metastatic prostate cancer patients.
Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer / B.A. Jereczek-Fossa, L. Fariselli, G. Beltramo, G. Catalano, F. Serafini, C. Garibaldi, R. Cambria, L. Brait, M. Possanzini, L.C. Bianchi, A. Vavassori, D. Zerini, F. Orsi, O. de Cobelli, R. Orecchia. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - 93:1(2009), pp. 14-17.
Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer
B.A. Jereczek-FossaPrimo
;O. de CobelliPenultimo
;R. OrecchiaUltimo
2009
Abstract
We report on 14 patients treated with linac- or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrence from prostate cancer, up to the mean dose of 30 Gy/3 fractions. At the mean follow-up of 18.6 months, five patients experienced clinical out-field progression. Toxicity was minimal. Further investigation is warranted in order to identify the patients that benefit most from this treatment modality and to define the optimal association of such local approach with androgen deprivation. Hopefully, effective local therapy might reduce the burden of systemic therapies given to the recurrent/metastatic prostate cancer patients.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.